Augere Medical Secures MDR CE-mark for its PolypAId™ Software and System
The MDR CE-mark is an important milestone for Augere Medical, enabling European launch of Augere’s PolypAId™ System for artificial intelligence (AI) assisted detection of polyps during colonoscopy colon cancer screening. After more than 10 years of basic research, product and clinical development, the Medical Device Regulation (MDR) CE-mark is a crucial milestone and enables Augere Medical to start commercial launch in geographies accepting the MDR CE-mark. The basic research originated from clinical needs identified by leading Scandinavian clinicians and research organizations